Sacituzumab shows modest benefit compared to standard chemotherapy in HR-positive patients treated with 2-4 prior lines of chemotherapy. Here is Hope Rugo discussing these findings:

Meaning: The results of this analysis of the monarchE randomized clinical trial found that treatment with adjuvant abemaciclib plus endocrine therapy demonstrated benefit for patients with hormone receptor–positive, ERBB2−, node-positive, and high-risk early breast cancer who received neoadjuvant chemotherapy before trial enrollment.

Recommendations: HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis.

Conclusion: A structured patient-centered pharmacy practice model integrating the ASCO/NCODA patient-centered standards and ongoing communication with patients and healthcare providers ensure timely refills, close monitoring, and allows patients to achieve high adherence and persistence rates comparable to those reported in clinical trials.

Conclusion: While prospective data are needed, analysis of real-world data suggests a survival benefit for continuation of a CDK4/6i beyond frontline progression for patients with HR /Her2− MBC.